Monoclonal antibodies against melanoma

US5610280A · kind A · utility

Assignee

• Boehringer Mannheim GmbH · DE

Inventors

• Michael Brandt · Iffeldorf, DE
• Josef Endl · Weilheim, DE
• Herbert Jungfer · Starnberg, DE
• Winfried Albert · Eberfing, DE

Key dates

• Filing date: Mar 15, 1994
• Grant date: Mar 11, 1997
• Expiry date: Mar 15, 2014

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention provides a human monoclonal antibody against melanoma, characterized in that it binds to the gangliosides GM3 and GD3 but essentially does not bind to the gangliosides GM1, GM2, GD1a, GD1b and GD2, the binding of the antibody to the gangliosides having been determined by immune staining after thin layer chromatographic separation of the gangliosides. The present invention also provides a process for the production of human monoclonal antibodies directed against melanoma, wherein, without previous immunization, B-lymphocytes are isolated from a healthy person, the isolated B-lymphocytes are immortalized, antibodies from the immortalized B-lymphocytes are screened by immune-histochemical analysis for binding against melanoma and/or melanoma metastases, the positively reacting B-lymphocytes are selected, cultured and monoclonal antibodies obtained therefrom.